Argen-X (ARGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Argen-X (ARGX) has a cash flow conversion efficiency ratio of 0.087x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€735.92 Million ≈ $860.37 Million USD) by net assets (€8.42 Billion ≈ $9.84 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Argen-X financial flexibility index to assess the company's free cash flow relative to its total liabilities.
Argen-X - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Argen-X's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see ARGX market cap overview for the company's overall valuation and market capitalisation.
Argen-X Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Argen-X ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
E.ON SE
F:EOAA
|
0.141x |
|
E.ON SE
F:EOAN
|
0.141x |
|
Xcel Energy Inc
NASDAQ:XEL
|
0.046x |
|
Ventas Inc
NYSE:VTR
|
0.037x |
|
Shengyi Technology Co Ltd
SHG:600183
|
0.061x |
|
DnB ASA
OL:DNB
|
-0.011x |
|
Thomson Reuters Corp
TO:TRI
|
0.065x |
|
Erste Group Bank AG
VI:EBS
|
-0.063x |
Annual Cash Flow Conversion Efficiency for Argen-X (2011–2025)
The table below shows the annual cash flow conversion efficiency of Argen-X from 2011 to 2025. View Argen-X stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €7.32 Billion ≈ $8.56 Billion |
€882.43 Million ≈ $1.03 Billion |
0.120x | +900.59% |
| 2024-12-31 | €5.50 Billion ≈ $6.43 Billion |
€-82.75 Million ≈ $-96.74 Million |
-0.015x | +85.33% |
| 2023-12-31 | €4.10 Billion ≈ $4.79 Billion |
€-420.33 Million ≈ $-491.41 Million |
-0.103x | +66.55% |
| 2022-12-31 | €2.81 Billion ≈ $3.29 Billion |
€-862.81 Million ≈ $-1.01 Billion |
-0.307x | -28.06% |
| 2021-12-31 | €2.53 Billion ≈ $2.96 Billion |
€-606.81 Million ≈ $-709.43 Million |
-0.239x | -0.60% |
| 2020-12-31 | €1.67 Billion ≈ $1.96 Billion |
€-398.46 Million ≈ $-465.85 Million |
-0.238x | -285.30% |
| 2019-12-31 | €1.18 Billion ≈ $1.38 Billion |
€151.63 Million ≈ $177.27 Million |
0.128x | +228.46% |
| 2018-12-31 | €615.87 Million ≈ $720.02 Million |
€-61.59 Million ≈ $-72.00 Million |
-0.100x | +5.62% |
| 2017-12-31 | €413.81 Million ≈ $483.79 Million |
€-43.84 Million ≈ $-51.26 Million |
-0.106x | -163.35% |
| 2016-12-31 | €66.65 Million ≈ $77.92 Million |
€11.15 Million ≈ $13.03 Million |
0.167x | +144.86% |
| 2015-12-31 | €40.76 Million ≈ $47.65 Million |
€-15.19 Million ≈ $-17.76 Million |
-0.373x | -256.64% |
| 2014-12-31 | €60.90 Million ≈ $71.20 Million |
€-6.37 Million ≈ $-7.44 Million |
-0.105x | +65.66% |
| 2013-12-31 | €29.97 Million ≈ $35.04 Million |
€-9.12 Million ≈ $-10.66 Million |
-0.304x | +54.29% |
| 2012-12-31 | €16.65 Million ≈ $19.47 Million |
€-11.09 Million ≈ $-12.96 Million |
-0.666x | -366.21% |
| 2011-12-31 | €27.90 Million ≈ $32.62 Million |
€-3.98 Million ≈ $-4.66 Million |
-0.143x | -- |
About Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develo… Read more